Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer

BACKGROUND: Pancreatic cancer remains one of the deadliest cancers due to lack of early detection and absence of effective treatments. Gemcitabine, the current standard-of-care chemotherapy for pancreatic cancer, has limited clinical benefit. Treatment of pancreatic cancer cells with gemcitabine has...

Descripción completa

Detalles Bibliográficos
Autores principales: Yip-Schneider, Michele T, Wu, Huangbing, Stantz, Keith, Agaram, Narasimhan, Crooks, Peter A, Schmidt, C Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672012/
https://www.ncbi.nlm.nih.gov/pubmed/23590467
http://dx.doi.org/10.1186/1471-2407-13-194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672012/
https://www.ncbi.nlm.nih.gov/pubmed/23590467
http://dx.doi.org/10.1186/1471-2407-13-194

Ejemplares similares